US pharmaceutical manufacturer Moderna has spread to the US Food and Drug Administration (FDA) for emergency approval of a second CoV booster vaccine for adults. “This application is based partly on recently published data obtained in the United States and Israel following the emergence of Omikron,” the company announced tonight.
Earlier in the week, manufacturers Biontech and Pfizer had also applied for emergency approval for an additional booster, i.e., the fourth dose in total – but only for people aged 65 and over.
According to Moderna, the application applies to all people aged 18 and over so that health authorities can determine the appropriate use of a second booster vaccination – for example, for those who would be at higher risk of Covid-19 because of their age or a previous illness.
Moderna also said research data had confirmed the effectiveness of the CoV vaccine. He noted that clinical trials continue for a booster tailored explicitly to the Omikron variant.
The vaccination rate in the USA is stagnating. Of the 330 million inhabitants, a good 65 percent have been vaccinated twice. A good 44 percent of this subgroup have received a booster vaccination.
- source: orf.at/picture: pixabay.com
This post has already been read 760 times!